9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 36

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Disease Controle Rate (DCR) at 12 weeks,  Safety: the incidence of adverse events, serious adverse events, deaths and laboratory abnormalities.,  Disease Controle Rate (DCR) at 6 months, Progression Free Survival (PFS)

Interventions: nivolumab and ipilimumab,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: December 2017

Completion Date: December 2019

Last  Posted Date: November 1, 2018

Location: Netherlands Cancer Institute-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, North-Holland, Netherlands

Website Link: https://ClinicalTrials.gov/show/NCT03048474

Was this article helpful?
Dislike 0